372 reports of this reaction
1.7% of all LOPERAMIDE HYDROCHLORIDE ORAL reports
#11 most reported adverse reaction
VOMITING is the #11 most commonly reported adverse reaction for LOPERAMIDE HYDROCHLORIDE ORAL, manufactured by AMERISOURCE BERGEN. There are 372 FDA adverse event reports linking LOPERAMIDE HYDROCHLORIDE ORAL to VOMITING. This represents approximately 1.7% of all 21,604 adverse event reports for this drug.
Patients taking LOPERAMIDE HYDROCHLORIDE ORAL who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
VOMITING is a less commonly reported adverse event for LOPERAMIDE HYDROCHLORIDE ORAL, but still significant enough to appear in the safety profile.
In addition to vomiting, the following adverse reactions have been reported for LOPERAMIDE HYDROCHLORIDE ORAL:
The following drugs have also been linked to vomiting in FDA adverse event reports:
VOMITING has been reported as an adverse event in 372 FDA reports for LOPERAMIDE HYDROCHLORIDE ORAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
VOMITING accounts for approximately 1.7% of all adverse event reports for LOPERAMIDE HYDROCHLORIDE ORAL, making it a notable side effect.
If you experience vomiting while taking LOPERAMIDE HYDROCHLORIDE ORAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.